Banks - Regional
Build Your Comparison
Side-by-side financial analysisStock Comparison
ECBK vs CARE vs JPM vs KO vs FIS
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Banks - Diversified
Beverages - Non-Alcoholic
Information Technology Services
ECBK vs CARE vs JPM vs KO vs FIS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Banks - Regional | Banks - Regional | Banks - Diversified | Beverages - Non-Alcoholic | Information Technology Services |
| Market Cap | $178M | $686M | $908.57B | $341.71B | $19.75B |
| Revenue (TTM) | $80M | $252M | $280.33B | $49.28B | $11.66B |
| Net Income (TTM) | $8M | $31M | $57.05B | $13.70B | $2.67B |
| Gross Margin | 39.9% | 61.2% | 60.0% | 61.7% | 37.6% |
| Operating Margin | 13.1% | 15.9% | 25.9% | 29.3% | 17.9% |
| Forward P/E | 21.6x | 5.7x | 14.6x | 24.3x | 6.1x |
| Total Debt | $285M | $179M | $942.38B | $45.49B | $4.01B |
| Cash & Equiv. | $95M | $105M | $343.34B | $10.27B | $599M |
ECBK vs CARE vs JPM vs KO vs FIS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 22 | Jun 26 | Return |
|---|---|---|---|
| ECB Bancorp, Inc. (ECBK) | 100 | 145.3 | +45.3% |
| Carter Bankshares, … (CARE) | 100 | 221.9 | +121.9% |
| JPMorgan Chase & Co. (JPM) | 100 | 281.9 | +181.9% |
| The Coca-Cola Compa… (KO) | 100 | 123.7 | +23.7% |
| Fidelity National I… (FIS) | 100 | 37.4 | -62.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ECBK vs CARE vs JPM vs KO vs FIS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ECBK has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 16.5%, EPS growth 95.8%
- 16.5% NII/revenue growth vs KO's 1.9%
- Beta 0.44 vs JPM's 0.87, lower leverage
CARE is the clearest fit if your priority is sleep-well-at-night and bank quality.
- Lower volatility, beta 0.50, Low D/E 42.5%, current ratio 0.75x
- NIM 2.7% vs ECBK's 2.0%
- +86.8% vs FIS's -50.4%
JPM is the clearest fit if your priority is long-term compounding.
- 481.2% 10Y total return vs CARE's 150.2%
KO is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 27.8% margin vs ECBK's 9.8%
- 13.1% ROA vs ECBK's 0.5%, ROIC 15.8% vs 1.8%
FIS ranks third and is worth considering specifically for income & stability and valuation efficiency.
- Dividend streak 1 yrs, beta 0.57, yield 4.3%
- PEG 0.25 vs KO's 2.17
- Beta 0.57, yield 4.3%, current ratio 0.59x
- Lower P/E (6.1x vs 24.3x), PEG 0.25 vs 2.17
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.5% NII/revenue growth vs KO's 1.9% | |
| Value | Lower P/E (6.1x vs 24.3x), PEG 0.25 vs 2.17 | |
| Quality / Margins | 27.8% margin vs ECBK's 9.8% | |
| Stability / Safety | Beta 0.44 vs JPM's 0.87, lower leverage | |
| Dividends | 4.3% yield, 1-year raise streak, vs KO's 2.6%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +86.8% vs FIS's -50.4% | |
| Efficiency (ROA) | 13.1% ROA vs ECBK's 0.5%, ROIC 15.8% vs 1.8% |
ECBK vs CARE vs JPM vs KO vs FIS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ECBK vs CARE vs JPM vs KO vs FIS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 2 of 6 categories
FIS leads 1 • ECBK leads 0 • CARE leads 0 • JPM leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 3525.9x ECBK's $80M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to ECBK's 9.8%. On growth, FIS holds the edge at +30.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $80M | $252M | $280.3B | $49.3B | $11.7B |
| EBITDAEarnings before interest/tax | $11M | $46M | $81.4B | $15.5B | $4.1B |
| Net IncomeAfter-tax profit | $8M | $31M | $57.0B | $13.7B | $2.7B |
| Free Cash FlowCash after capex | $9M | $30M | $100.9B | $12.6B | $2.8B |
| Gross MarginGross profit ÷ Revenue | +39.9% | +61.2% | +60.0% | +61.7% | +37.6% |
| Operating MarginEBIT ÷ Revenue | +13.1% | +15.9% | +25.9% | +29.3% | +17.9% |
| Net MarginNet income ÷ Revenue | +9.8% | +12.5% | +20.4% | +27.8% | +22.9% |
| FCF MarginFCF ÷ Revenue | +11.3% | +11.9% | +36.0% | +25.5% | +23.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | +12.1% | +30.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +82.4% | +8.3% | +16.0% | +18.2% | +30.6% |
Valuation Metrics
FIS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 16.2x trailing earnings, JPM trades at a 68% valuation discount to FIS's 50.9x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs KO's 2.34x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $178M | $686M | $908.6B | $341.7B | $19.7B |
| Enterprise ValueMkt cap + debt − cash | $368M | $759M | $1.51T | $376.9B | $23.2B |
| Trailing P/EPrice ÷ TTM EPS | 21.61x | 22.11x | 16.22x | 26.12x | 50.95x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.67x | 14.60x | 24.27x | 6.09x |
| PEG RatioP/E ÷ EPS growth rate | 1.16x | — | 0.92x | 2.34x | 2.09x |
| EV / EBITDAEnterprise value multiple | 35.47x | 18.98x | 18.52x | 25.45x | 6.36x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 2.69x | 3.25x | 7.13x | 1.85x |
| Price / BookPrice ÷ Book value/share | 0.98x | 1.66x | 2.51x | 9.99x | 1.43x |
| Price / FCFMarket cap ÷ FCF | 19.80x | 21.57x | 9.01x | 64.52x | 7.03x |
Profitability & Efficiency
KO leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $5 for ECBK. FIS carries lower financial leverage with a 0.29x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CARE scores 8/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.6% | +7.6% | +15.9% | +41.1% | +18.4% |
| ROA (TTM)Return on assets | +0.5% | +0.7% | +1.3% | +13.1% | +7.5% |
| ROICReturn on invested capital | +1.8% | +5.7% | +4.5% | +15.8% | +6.0% |
| ROCEReturn on capital employed | +2.3% | +1.5% | +8.9% | +17.3% | +6.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 8 | 5 | 7 | 6 |
| Debt / EquityFinancial leverage | 1.66x | 0.43x | 2.60x | 1.33x | 0.29x |
| Net DebtTotal debt minus cash | $190M | $73M | $599.0B | $35.2B | $3.4B |
| Cash & Equiv.Liquid assets | $95M | $105M | $343.3B | $10.3B | $599M |
| Total DebtShort + long-term debt | $285M | $179M | $942.4B | $45.5B | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 0.22x | 0.39x | 0.74x | 10.70x | 21.16x |
Total Returns (Dividends Reinvested)
Evenly matched — CARE and JPM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $23,985 today (with dividends reinvested), compared to $3,259 for FIS. Over the past 12 months, CARE leads with a +86.8% total return vs FIS's -50.4%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs FIS's -7.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +17.3% | +59.9% | +0.8% | +16.4% | -40.4% |
| 1-Year ReturnPast 12 months | +34.3% | +86.8% | +20.9% | +17.7% | -50.4% |
| 3-Year ReturnCumulative with dividends | +55.6% | +103.8% | +138.8% | +39.3% | -21.0% |
| 5-Year ReturnCumulative with dividends | +44.1% | +139.8% | +135.5% | +65.3% | -67.4% |
| 10-Year ReturnCumulative with dividends | +44.1% | +150.2% | +481.2% | +115.0% | -26.7% |
| CAGR (3Y)Annualised 3-year return | +15.9% | +26.8% | +33.7% | +11.7% | -7.6% |
Risk & Volatility
Evenly matched — ECBK and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than JPM's 0.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ECBK currently trades 99.1% from its 52-week high vs FIS's 46.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.45x | 0.50x | 0.87x | -0.24x | 0.58x |
| 52-Week HighHighest price in past year | $20.50 | $31.40 | $338.09 | $84.04 | $82.74 |
| 52-Week LowLowest price in past year | $14.82 | $16.27 | $269.72 | $65.35 | $37.85 |
| % of 52W HighCurrent price vs 52-week peak | +99.1% | +98.6% | +96.2% | +94.5% | +46.2% |
| RSI (14)Momentum oscillator 0–100 | 59.4 | 76.8 | 72.1 | 49.2 | 35.2 |
| Avg Volume (50D)Average daily shares traded | 11K | 323K | 7.4M | 13.6M | 5.7M |
Analyst Outlook
Evenly matched — KO and FIS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CARE as "Hold", JPM as "Buy", KO as "Buy", FIS as "Buy". Consensus price targets imply 64.6% upside for FIS (target: $63) vs -7.9% for CARE (target: $29). For income investors, FIS offers the higher dividend yield at 4.27% vs JPM's 1.83%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $28.50 | $339.75 | $86.13 | $62.88 |
| # AnalystsCovering analysts | — | 5 | 61 | 48 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.8% | +2.6% | +4.3% |
| Dividend StreakConsecutive years of raises | — | 0 | 15 | 56 | 1 |
| Dividend / ShareAnnual DPS | — | — | $5.95 | $2.04 | $1.63 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.6% | +2.9% | +3.8% | +0.2% | +7.2% |
KO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). FIS leads in 1 (Valuation Metrics). 3 tied.
ECBK vs CARE vs JPM vs KO vs FIS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ECBK or CARE or JPM or KO or FIS a better buy right now?
For growth investors, ECB Bancorp, Inc.
(ECBK) is the stronger pick with 16. 5% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ECBK or CARE or JPM or KO or FIS?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 2x versus Fidelity National Information Services, Inc. at 50. 9x. On forward P/E, Carter Bankshares, Inc. is actually cheaper at 5. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Fidelity National Information Services, Inc. wins at 0. 25x versus The Coca-Cola Company's 2. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ECBK or CARE or JPM or KO or FIS?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +139. 8%, compared to -67. 4% for Fidelity National Information Services, Inc. (FIS). Over 10 years, the gap is even starker: JPM returned +481. 2% versus FIS's -26. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ECBK or CARE or JPM or KO or FIS?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
24β versus JPMorgan Chase & Co. 's 0. 87β — meaning JPM is approximately -468% more volatile than KO relative to the S&P 500. On balance sheet safety, Fidelity National Information Services, Inc. (FIS) carries a lower debt/equity ratio of 29% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ECBK or CARE or JPM or KO or FIS?
By revenue growth (latest reported year), ECB Bancorp, Inc.
(ECBK) is pulling ahead at 16. 5% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: ECB Bancorp, Inc. grew EPS 95. 8% year-over-year, compared to -47. 2% for Fidelity National Information Services, Inc.. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ECBK or CARE or JPM or KO or FIS?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus 3. 6% for Fidelity National Information Services, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 13. 1% for ECBK. At the gross margin level — before operating expenses — CARE leads at 61. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ECBK or CARE or JPM or KO or FIS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Fidelity National Information Services, Inc. (FIS) is the more undervalued stock at a PEG of 0. 25x versus The Coca-Cola Company's 2. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Carter Bankshares, Inc. (CARE) trades at 5. 7x forward P/E versus 24. 3x for The Coca-Cola Company — 18. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FIS: 64. 6% to $62. 88.
08Which pays a better dividend — ECBK or CARE or JPM or KO or FIS?
In this comparison, FIS (4.
3% yield), KO (2. 6% yield), JPM (1. 8% yield) pay a dividend. ECBK, CARE do not pay a meaningful dividend and should not be held primarily for income.
09Is ECBK or CARE or JPM or KO or FIS better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
24), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, ECBK: +44. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ECBK and CARE and JPM and KO and FIS?
These companies operate in different sectors (ECBK (Financial Services) and CARE (Financial Services) and JPM (Financial Services) and KO (Consumer Defensive) and FIS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ECBK is a small-cap high-growth stock; CARE is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock; FIS is a mid-cap income-oriented stock. JPM, KO, FIS pay a dividend while ECBK, CARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.